The study evaluated NCX 226, in comparison with bosentan, in a preclinical model of pulmonary fibrosis induced by bleomycin.
The results of the trial suggested that NCX 226 and bosentan counteract lung inflammation and airway stiffness in this preclinical model.
NCX 226 showed improved efficacy over bosentan in preventing bleomycin-induced airway stiffness and in reducing key inflammatory parameters, such as leukocyte infiltration, secretion of the profibrotic cytokine TGF-beta and oxidative stress markers.